Morgan Stanley analyst Matthew Harrison maintained a Hold rating on ADC Therapeutics (ADCT – Research Report) today and set a price target of $5.00. The company’s shares opened today at $4.85.
According to TipRanks, Harrison is a 5-star analyst with an average return of 7.9% and a 53.46% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Editas Medicine.
ADC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.20.
See the top stocks recommended by analysts >>
ADCT market cap is currently $361.5M and has a P/E ratio of -2.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company’s product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
Read More on ADCT:
